Literature DB >> 656355

Long-term hypotensive effect of atenolol 4% eyedrops.

R F Brenkman.   

Abstract

The effect of long-term application of 4% atenolol eye drops has been studied in patients with either glaucoma or ocular hypertension. In some patients who show a good initial response the ocular hypotensive effect gradually wears off with long-term use. This pattern of response appears to be more frequent in patients with pretreatment intraocular pressure of 25 mmHg, or greater. In combination with atenolol miotics or adrenaline show an additive effect.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 656355      PMCID: PMC1043215          DOI: 10.1136/bjo.62.5.287

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  9 in total

1.  Effect of oral administration of various beta-blocking agents on the intraocular pressure in healthy volunteers.

Authors:  K Wettrell; M Pandolfi
Journal:  Exp Eye Res       Date:  1975-11       Impact factor: 3.467

2.  Proceedings: Adrenergic tachyphylaxis in animal and human eyes.

Authors:  M E Langham
Journal:  Exp Eye Res       Date:  1975-02       Impact factor: 3.467

3.  Ocular hypotensive effect of atenolol (Tenormin, I.C.I.). A new beta-adrenergic blocker.

Authors:  M J Elliot; P M Cullen; C I Phillips
Journal:  Br J Ophthalmol       Date:  1975-06       Impact factor: 4.638

4.  Effect of DL- and D-propranolol on oscular tension in rabbits and patients.

Authors:  J Vale; C I Phillips
Journal:  Exp Eye Res       Date:  1970-01       Impact factor: 3.467

5.  A comparison of the ocular hypotensive actions of salbutamol and adrenaline in chronic simple glaucoma.

Authors:  G D Paterson; G Paterson
Journal:  Postgrad Med J       Date:  1971-03       Impact factor: 2.401

6.  Propranolol as ocular hypotensive agent.

Authors:  C I Phillips; G Howitt; D J Rowlands
Journal:  Br J Ophthalmol       Date:  1967-04       Impact factor: 4.638

7.  Atenolol versus propranolol. A comparison of ocular hypotensive effect of an oral dose.

Authors:  M J Macdonald; P M Cullen; C I Phillips
Journal:  Br J Ophthalmol       Date:  1976-11       Impact factor: 4.638

8.  Pathology of practolol-induced ocular toxicity.

Authors:  A H Rahi; C M Chapman; A Garner; P Wright
Journal:  Br J Ophthalmol       Date:  1976-05       Impact factor: 4.638

9.  Practolol (Eraldin) eye drops as an ocular hypotensive agent.

Authors:  J Vale; C I Phillips
Journal:  Br J Ophthalmol       Date:  1973-03       Impact factor: 4.638

  9 in total
  8 in total

1.  The treatment of glaucoma: role of beta-blocking agents.

Authors:  W P Boger
Journal:  Drugs       Date:  1979-07       Impact factor: 9.546

2.  Effect of orally administered nadolol on the intraocular pressure in normal volunteers.

Authors:  J Williamson; H R Atta; P A Kennedy; J G Muir
Journal:  Br J Ophthalmol       Date:  1985-01       Impact factor: 4.638

3.  Comparison of ocular hypotensive effects of 3 dosages of oral atenolol.

Authors:  M K Tutton; R J Smith
Journal:  Br J Ophthalmol       Date:  1983-10       Impact factor: 4.638

4.  A dose-response study of oral atenolol administered once daily in patients with raised intra-ocular pressure.

Authors:  E Stenkula; K Wettrell
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1982       Impact factor: 3.117

5.  [The effect of timolol and parasympathicomimetica in the treatment of the elevated intraocular pressure (author's transl)].

Authors:  M Ober; A Scharrer
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1979-07-02

Review 6.  Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.

Authors:  A M Brooks; W E Gillies
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

Review 7.  Timolol: a review of its therapeutic efficacy in the topical treatment of glaucoma.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-01       Impact factor: 9.546

8.  Atenolol 4% eyedrops in glaucoma simplex.

Authors:  C C Sterk
Journal:  Doc Ophthalmol       Date:  1980-04-15       Impact factor: 2.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.